Plain-English translation of NCT07616687 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing , a newer biologic medication for Crohn's disease, to see how well it works in real-world settings. The study will look at whether increasing the dose of this medication helps people whose disease isn't controlled on the standard dose, or people who don't respond well at the start of treatment. Researchers want to understand what factors help predict who will benefit from a stronger dose.
Some people with Crohn's disease don't respond well enough to the standard dose of newer medications, and others lose their response over time. This study aims to find out whether increasing the dose can help these patients get their disease under control.
You likely qualify if…
You likely don't qualify if…
You would receive the medication as injections, starting with the standard dose. Your doctor will monitor how well you respond using symptom checks and blood or stool tests. If your disease isn't controlled or you're not responding well after 12 weeks, your dose may be increased. The study lasts one year and involves visits to measure how the treatment is working.
AI-generated summary from trial data · Jul 16, 2026 · Not medical advice
France